Program
Anti-PD-1/IL-15 Fusion Protein JMT108
Also written as “JMT108”, “SYS6090 Injection + Bevacizumab Injection” and “SYS6090 Injection +SYS6043 Injection +Bevacizumab Injection”.
Its studies are mostly in Melanoma · Carcinoma, Hepatocellular · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Neoplasms, led by 2 companies.
Drug pageAnti-PD-1/IL-15 Fusion Protein JMT108: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Groupits history only | 55 open or running | phase 2since Mar 6, 2025 | Mar 6, 2025 | Nov 30, 2026phase 2 · NCT07280832 |
| Conjupro Biotherapeuticsits history only | 11 open or running | phase 1since Nov 25, 2025 | Nov 25, 2025 | Jul 2029phase 1 · NCT07317505 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 6, 2025First study: phase 2 study in Advanced Malignant TumorsNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT06877650 · 436 planned · China
- Nov 25, 2025Conjupro Biotherapeutics’ first study: phase 1 study in NeoplasmsNew to Conjupro BiotherapeuticsConjupro Biotherapeutics · NCT07317505 · 270 planned · United States
- Nov 28, 2025Phase 2 study in MelanomaCSPC Pharmaceutical Group · NCT07280832 · 500 planned · China
- Feb 4, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT07472647 · 596 planned
- Jul 30, 2026Phase 2 study in Carcinoma, HepatocellularCSPC Pharmaceutical Group · NCT07761286 · 288 planned · China
- Aug 2, 2026Phase 2 study in Colorectal NeoplasmsCSPC Pharmaceutical Group · NCT07750041 · 260 planned · China
Ahead
- Nov 30, 2026Primary completion: phase 2 study in MelanomaCSPC Pharmaceutical Group · NCT07280832
- Dec 31, 2027Primary completion: phase 2 study in Colorectal NeoplasmsCSPC Pharmaceutical Group · NCT07750041
- Mar 30, 2028Primary completion: phase 2 study in Advanced Malignant TumorsCSPC Pharmaceutical Group · NCT06877650
- Feb 28, 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT07472647
TargetBeta
“A recombinant fusion protein composed of an antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) ”NCIt, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07750041Colorectal Neoplasms · China | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Dec 31, 2027 | 260 |
| NCT07761286Carcinoma, Hepatocellular · China | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Sep 30, 2029 | 288 |
| NCT07472647Carcinoma, Non-Small-Cell Lung | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Feb 28, 2029 | 596 |
| NCT07280832Melanoma · China | 2 | Recruiting | CSPC Pharmaceutical Group | Nov 30, 2026 | 500 |
| NCT07317505Neoplasms · United States | 1 | Recruiting | Conjupro Biotherapeutics | Jul 2029 | 270 |
| NCT06877650Advanced Malignant Tumors · China | 2 | Recruiting | CSPC Pharmaceutical Group | Mar 30, 2028 | 436 |
How it is read
Names in the registry
- “JMT108”, 3 entries
- “SYS6090 Injection + Bevacizumab Injection”, 1 entry
- “SYS6090 Injection +SYS6043 Injection +Bevacizumab Injection”, 1 entry
- “SYS6090 (Fixed Dose Level A) + bevacizumab”, 1 entry
- “SYS6090 (Fixed Dose Level B ) + bevacizumab”, 1 entry
Conditions, from the studies’ own filings
- Melanoma, 1 study
- Carcinoma, Hepatocellular, 1 study
- Colorectal Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.